Exploring the Mechanisms of Pathogenesis in Prostate Cancer Involving TMPRSS2-ERG (Or ETV1) Gene Rearrangement

2009 ◽  
Author(s):  
Stuart H. Orkin
Keyword(s):  
Prostate Cancer ◽  
Gene Rearrangement

Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update

2009 ◽  
Vol 133 (7) ◽  
pp. 1033-1040 ◽  
Author(s):  
A. Craig Mackinnon ◽  
Benjamin C. Yan ◽  
Loren J. Joseph ◽  
Hikmat A. Al-Ahmadie
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Molecular Biology ◽  
Gene Rearrangement ◽  
Molecular Characteristics ◽  
Early Event ◽  
Ablation Therapy ◽  
Androgen Ablation ◽  
Development Of Resistance ◽  
Prostate Cancers

Abstract Context.—Recent studies have uncovered a number of possible mechanisms by which prostate cancers can become resistant to systemic androgen deprivation, most involving androgen-independent reactivation of the androgen receptor. Genome-wide expression analysis with microarrays has identified a wide array of genes that are differentially expressed in metastatic prostate cancers compared to primary nonrecurrent tumors. Recently, recurrent gene fusions between TMPRSS2 and ETS family genes have been identified and extensively studied for their role in prostatic carcinoma. Objective.—To review the recent developments in the molecular biology of prostate cancer, including those pertaining to the androgen receptor and the newly identified TMPRSS2-related translocations. Data Sources.—Literature review and personal experience. Conclusions.—Prostatic adenocarcinoma is a heterogeneous group of neoplasms with a broad spectrum of pathologic and molecular characteristics and clinical behaviors. Numerous mechanisms contribute to the development of resistance to androgen ablation therapy, resulting in ligand-independent reactivation of the androgen receptor, including amplification, mutation, phosphorylation, and activation of coreceptors. Multiple translocations of members of the ETS oncogene family are present in approximately half of clinically localized prostate cancers. TMPRSS2:ERG gene rearrangement appears to be an early event in prostate cancer and is not observed in benign or hyperplastic prostatic epithelium. Duplication of TMPRSS2:ERG appears to predict a worse prognosis. The relationship between TMPRSS2:ERG gene rearrangement and other morphologic and prognostic parameters of prostate cancer is still unclear.

Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 36-36
Author(s):  
E. A. Klein ◽  
S. M. Falzarano ◽  
T. Maddala ◽  
D. Cherbavaz ◽  
W. F. Novotny ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Gleason Score ◽  
Clinical Data ◽  
Gene Rearrangement ◽  
Clinical Stage ◽  
Clinical Recurrence ◽  
Psa Recurrence ◽  
Stage T1

36 Background: The association of TMPRSS2-ERG fusions and ERG expression in prostate cancer (PC) with adverse clinical outcomes has been controversial, with mixed results in the literature. We conducted a study to test whether tumor-derived gene expression profiles, including the presence of TMPRSS2-ERG fusions and ERG gene expression, are associated with clinical recurrence (cR) after radical prostatectomy (RP). Methods: All patients with clinical stage T1/T2 prostate cancer treated with RP at CC from 1987 to 2004 were identified (n∼f2,600). A cohort sampling design was used to select 127 patients with cR and 374 patients without cR after RP. For each patient a primary Gleason pattern (GP) sample, secondary (or highest) GP sample, and an adjacent nontumor tissue sample were evaluated. Surgical Gleason Score (GS) and clinical data were centrally reviewed. RNA was extracted from 6 manually dissected 10 μ m formalin-fixed paraffin-embedded sections obtained from RP specimens and expression of TMPRSS2-ERGa, TMPRSS2-ERGb, ERG and reference genes were quantified using RT-PCR. Times to cR, PSA recurrence, and PC death were analyzed using Cox PH regression. Results: Blocks from 441 patients were evaluable. Median F/U was 5.8 years. Patients were mostly Caucasian (83%), clinical stage T1 (66%), had baseline PSA <10 ng/mL (82%), and had surgical Gleason score ≤7 (87%). 848 tumor samples and 410 non-tumor samples were assessed. TMPRSS2-ERGa and/or TMPRSS2-ERGb fusions were present in 51.8% of tumor samples and 7.5% of non-tumor samples. There was 89% concordance (95% CI: 86%, 92%) for TMPRSS2-ERG fusion status between the 2 tumor samples for each patient. High ERG expression was strongly associated with the presence of TMPRSS2-ERG fusions (p <0.01). We did not find an association between TMPRSS2-ERG a/b gene rearrangement or ERG expression with cR, PSA recurrence, PC death, or surgical GS (p > 0.2). Conclusions: This study was notable for the large number of cR events, use of a standardized quantitative assay, and rigorous central review of pathology and clinical data. We did not find an association of TMPRSS2-ERG gene rearrangements or ERG expression with aggressiveness of prostate cancer post RP. [Table: see text]

scholarly journals Detecting Cancer Outlier Genes with Potential Rearrangement Using Gene Expression Data and Biological Networks

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Mohammed Alshalalfa ◽  
Tarek A. Bismar ◽  
Reda Alhajj
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
Biological Networks ◽  
Gene Rearrangement ◽  
Real Data ◽  
Outcome Data ◽  
Expression Data ◽  
Excellent Performance ◽  
Functional Protein ◽  
Gene Alterations

Gene alterations are a major component of the landscape of tumor genomes. To assess the significance of these alterations in the development of prostate cancer, it is necessary to identify these alterations and analyze them from systems biology perspective. Here, we present a new method (EigFusion) for predicting outlier genes with potential gene rearrangement. EigFusion demonstrated excellent performance in identifying outlier genes with potential rearrangement by testing it to synthetic and real data to evaluate performance. EigFusion was able to identify previously unrecognized genes such as FABP5 and KCNH8 and confirmed their association with primary and metastatic prostate samples while confirmed the metastatic specificity for other genes such as PAH, TOP2A, and SPINK1. We performed protein network based approaches to analyze the network context of potential rearranged genes. Functional gene rearrangement Modules are constructed by integrating functional protein networks. Rearranged genes showed to be highly connected to well-known altered genes in cancer such as AR, RB1, MYC, and BRCA1. Finally, using clinical outcome data of prostate cancer patients, potential rearranged genes demonstrated significant association with prostate cancer specific death.

ERG gene rearrangement status in prostate cancer detected by immunohistochemistry

2011 ◽  
Vol 459 (4) ◽  
pp. 441-447 ◽  
Author(s):  
Sara Moscovita Falzarano ◽  
Ming Zhou ◽  
Paula Carver ◽  
Toyonori Tsuzuki ◽  
Kelly Simmerman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Rearrangement

2223 ERG GENE REARRANGEMENT IS MORE FREQUENT IN EARLY-ONSET PROSTATE CANCER AND IS ASSOCIATED WITH LOWER PSA SERUM LEVELS IN YOUNGER PATIENTS IN A PSA SCREENING COHORT

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Georg Schaefer ◽  
Reinhold Ramoner ◽  
Wolfgang Horninger ◽  
Jasmin Bektic ◽  
Francesca Demichelis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Onset ◽  
Gene Rearrangement ◽  
Serum Levels ◽  
Younger Patients ◽  
Psa Screening

scholarly journals Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

2009 ◽  
Vol 101 (7) ◽  
pp. 1137-1144 ◽  
Author(s):  
C S Foster ◽  
◽  
A R Dodson ◽  
L Ambroisine ◽  
G Fisher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Gene Rearrangement ◽  
Poor Clinical Outcome ◽  
Hsp 27

Sigmoidoscopic findings following radiation for prostate cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
T BOLIN ◽  
A KNEEBONE ◽  
T LARSSON
Keyword(s):  
Prostate Cancer

1625: Neuroligin 4 ISOFORM Y: A Novel Marker for Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 538-539
Author(s):  
Joseph F. Pazona ◽  
C. Shad Thaxton ◽  
Neema Navai ◽  
Brian T. Helfand ◽  
Lee C. Zhao ◽  
...  
Keyword(s):  
Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document